Small Molecules
9 September 2013
Adamis Announces Positive Results of Study Concerning C31G in Treating Herpes Simplex Virus (HSV) Eye Infection6 September 2013
Viamet Pharmaceuticals Initiates Phase 2 Clinical Program with Novel Antifungal Agent VT-11616 September 2013
The collaboration with Daewoong Pharmaceutical for the development of the hepatitis B compound, MIV-210 has been discontinued5 September 2013
Investigational Submicron Diclofenac Reduces Use of Opioid Rescue Medication in Post-Surgical Pain in a Phase 3 Study5 September 2013
Civitas Therapeutics Initiates Phase 2b Clinical Study of CVT-301, Inhaled L-dopa for Parkinson’s Disease5 September 2013
FDA Accepts Endo’s Complete Response Submission to New Drug Application for AVEED™ (Testosterone Undecanoate) Injection5 September 2013
Chelsea Therapeutics Announces FDA Acceptance of NORTHERA(TM) (droxidopa) NDA Resubmission5 September 2013
Theravance Announces Positive Results From Phase 2b Study 0091 With Its LAMA Candidate, TD-4208, for the Treatment of COPD5 September 2013
Bayer’s Regorafenib Submitted for European Marketing Authorization for the Treatment of Gastrointestinal Stromal Tumors (GIST)4 September 2013
Mallinckrodt Pharmaceuticals Reports Human Abuse Liability (HAL) Data for MNK-795, an Extended-Release Oxycodone/Acetaminophen Combination4 September 2013
KemPharm Continues to Expand its Pain Therapy Pipeline with Discovery of KP606, a Novel Prodrug of Oxycodone4 September 2013
Endo and BioDelivery Sciences Provide Update on BEMA Buprenorphine Phase III Development Program4 September 2013
Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome4 September 2013
AstraZeneca initiates Phase III clinical programme for olaparib, a treatment in development for patients with BRCA mutated ovarian cancer3 September 2013
Tetraphase Doses First Patient in Phase 3 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections3 September 2013
Zalicus Completes Patient Enrollment in Two Phase 2 Clinical Studies of Z160 for Chronic Neuropathic Pain3 September 2013
Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv MecarbilNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports